Raphas Co. Ltd - Asset Resilience Ratio

Latest as of September 2025: 7.27%

Raphas Co. Ltd (214260) has an Asset Resilience Ratio of 7.27% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Raphas Co. Ltd debt and liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

₩6.02 Billion
≈ $4.08 Million USD Cash + Short-term Investments

Total Assets

₩82.76 Billion
≈ $56.08 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2017–2024)

This chart shows how Raphas Co. Ltd's Asset Resilience Ratio has changed over time. See Raphas Co. Ltd (214260) net assets for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Raphas Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Raphas Co. Ltd market capitalisation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ₩0.00 0%
Short-term Investments ₩6.02 Billion 7.27%
Total Liquid Assets ₩6.02 Billion 7.27%

Asset Resilience Insights

  • Limited Liquidity: Raphas Co. Ltd maintains only 7.27% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Raphas Co. Ltd Industry Peers by Asset Resilience Ratio

Compare Raphas Co. Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Fortress Biotech Inc
NASDAQ:FBIO
Biotechnology 11.59%
Summit Therapeutics PLC
NASDAQ:SMMT
Biotechnology 0.00%
Tubize-Fin
BR:TUB
Biotechnology 0.05%
Apellis Pharmaceuticals Inc
NASDAQ:APLS
Biotechnology 0.58%
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
Biotechnology 8.08%
BrightGene Bio Medical Technology C
SHG:688166
Biotechnology 1.00%
BioArctic AB (publ)
ST:BIOA-B
Biotechnology 72.35%
Chengzhi Shareholding Co Ltd
SHE:000990
Biotechnology 6.73%

Annual Asset Resilience Ratio for Raphas Co. Ltd (2017–2024)

The table below shows the annual Asset Resilience Ratio data for Raphas Co. Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 9.66% ₩7.35 Billion
≈ $4.98 Million
₩76.09 Billion
≈ $51.57 Million
-12.02pp
2023-12-31 21.69% ₩21.78 Billion
≈ $14.76 Million
₩100.40 Billion
≈ $68.04 Million
-11.09pp
2022-12-31 32.78% ₩31.49 Billion
≈ $21.34 Million
₩96.06 Billion
≈ $65.10 Million
-13.44pp
2021-12-31 46.22% ₩45.22 Billion
≈ $30.65 Million
₩97.84 Billion
≈ $66.31 Million
+22.39pp
2020-12-31 23.83% ₩14.25 Billion
≈ $9.66 Million
₩59.83 Billion
≈ $40.54 Million
-2.48pp
2019-12-31 26.30% ₩16.54 Billion
≈ $11.21 Million
₩62.88 Billion
≈ $42.62 Million
+12.85pp
2018-12-31 13.45% ₩4.64 Billion
≈ $3.15 Million
₩34.51 Billion
≈ $23.39 Million
-15.59pp
2017-12-31 29.04% ₩10.11 Billion
≈ $6.85 Million
₩34.81 Billion
≈ $23.59 Million
--
pp = percentage points

About Raphas Co. Ltd

KQ:214260 Korea Biotechnology
Market Cap
$54.13 Million
₩79.88 Billion KRW
Market Cap Rank
#21593 Global
#1397 in Korea
Share Price
₩9500.00
Change (1 day)
-1.96%
52-Week Range
₩9320.00 - ₩21150.00
All Time High
₩75400.00
About

Raphas Co., Ltd. manufactures and sells biodegradable microneedles in Korea. The company offers skin care, medical device, whitening care, and wrinkle care under the Acropass brand; and health food product under the FitKong brand. It also supplies double-layer microneedle manufacturing technology; and provides original development manufacturing, and contract development and manufacturing organiza… Read more